MiRNA-125a-5p: A regulator and predictor of gefitinib's effect on nasopharyngeal carcinoma

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Liu, Yanyang ^a   Li, Zhixi ^a   Wu, Lu ^a   Wang, Zi ^a   Wang, Xia ^a   Yu, Yang ^a   Zhao, Qian ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Gefitinib; miR 125a 5p; MiRNA; Nasopharyngeal carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCEIN ISOTHIOCYANATE; GEFITINIB; LIPOCORTIN 5; MICRORNA; MICRORNA 125A 5P; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84897954195     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-24     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol 2007, 25(16):2152-2155. 10.1200/JCO.2007.10.9017, 17538157.
3. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther 2010, 10(7):673-681. 10.4161/cbt.10.7.12793, 20647773.
4. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003, 39(4):361-366. 10.1016/S1368-8375(02)00120-3, 12676255.
5. Chua DT, Wie WI, Wong MP, Sham JS, Nicholls J, Au GK. FRCR: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008, 30(7):863-867. 10.1002/hed.20792, 18213730.
6. Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, Chan AT. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol 2008, 62(1):59-64. 10.1007/s00280-007-0575-8, 17762933.
7. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500. 10.1126/science.1099314, 15118125.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938, 15118073.
9. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005, 102(52):19075-19080. 10.1073/pnas.0509603102, 1323209, 16365291.
10. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Leendert LH, Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124(6):1169-1181. 10.1016/j.cell.2006.02.037, 16564011.
11. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miR Base: tools for microRNA genomics. Nucleic Acids Res 2008, 36(suppl1):D154-D158. 2238936, 17991681.
12. Kloosterman WP, Plasterk RHA. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11(4):441-450. 10.1016/j.devcel.2006.09.009, 17011485.
13. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269. 10.1038/nrc1840, 16557279.
14. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
15. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866. 10.1038/nrc1997, 17060945.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008, 105(30):10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
17. Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, Wu M, Zhou M, Shen S, Xiaoling L, Niu Z, Zhang W, Shi L, Xiang B, Lu J, Wang L, Li D, Tang H, Li G. microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis 2010, 31(4):559-566. 10.1093/carcin/bgp335, 20053927.
18. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci 2008, 105(15):5874-5878. 10.1073/pnas.0801130105, 2311339, 18390668.
19. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo-and radiotherapy in different tumour types. Eur J Cancer 2010, 46(2):298-311. 10.1016/j.ejca.2009.10.027, 19948396.
20. Jiang L, Huang Q, Chang J, Wang E, Qiu X. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res 2011, 37(7):387-398. 10.3109/01902148.2010.492068, 21777146.
21. Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC. p53 enhances Gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res 2007, 67(3):1163-1169. 10.1158/0008-5472.CAN-06-2037, 17283151.
22. Zhanga Y, Gao JS, Tang X, Tucker LD, Quesenberry P, Rigoutsos I, Ramratnam B. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 2009, 583(22):3725-3730. 10.1016/j.febslet.2009.10.002, 3594778, 19818772.
23. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007, 282(2):1479-1486. 10.1074/jbc.M609383200, 17110380.
24. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011, 17(9):2725-2733. 10.1158/1078-0432.CCR-10-2132, 21220473.
25. Ise N, Omi K, Nambara D, Higashiyama S, Goishi K. Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors. Anticancer Res 2011, 31(12):4155-4161.
26. Ma BB, Lui VW, Poon FF, Wong SC, To KF, Wong E, Chen H, Lo KW, Tao Q, Chan AT. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 2010, 28(3):326-333. 10.1007/s10637-009-9316-7, 2953619, 19756373.
27. Ma R, Jiang T, Kang Jiang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 2012, 31(1):38. 10.1186/1756-9966-31-38, 3431991, 22546315.
28. Tie Y, Liu BD, HanJiang F, Zheng XF. Circulating miRNA and cancer diagnosis. Sci China Ser C Life Sci 2009, 52(12):1117-1122.
29. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005, 20(3):1005-1015.